Induction of tolerance in organ recipients by hematopoietic stem cell transplantation

International Immunopharmacology

Volumn 9, Issue 6, 2009, Pages 694-700

  Ophir, Eran ^a   Reisner, Yair ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Anti 3rd party CTLs; Megadose transplant; Mixed chimerism; Veto

Indexed keywords

CD34 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2;

ADOPTIVE TRANSFER; ARTICLE; CYTOTOXIC T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; NONHUMAN; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SEVERE COMBINED IMMUNODEFICIENCY; TRANSPLANTATION TOLERANCE;

ANIMALS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION CONDITIONING; TRANSPLANTATION TOLERANCE;

EID: 65349090665     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.12.009     Document Type: Article

References (60)

1. Kingsley C.I., Nadig S.N., and Wood K.J. Transplantation tolerance: lessons from experimental rodent models. Transpl Int 20 10 (2007) 828-841
2. Scandling J.D., Busque S., Dejbakhsh-Jones S., Benike C., Millan M.T., Shizuru J.A., et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 358 4 (2008) 362-368
3. Kawai T., Cosimi A.B., Spitzer T.R., Tolkoff-Rubin N., Suthanthiran M., Saidman S.L., et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 358 4 (2008) 353-361
4. Tomita Y., Khan A., and Sykes M. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen. J Immunol 153 3 (1994) 1087-1098
5. Tomita Y., Sachs D.H., Khan A., and Sykes M. Additional monoclonal antibody (mAB) injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation. Transplantation 61 3 (1996) 469-477
6. Wekerle T., Kurtz J., Ito H., Ronquillo J.V., Dong V., Zhao G., et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 6 4 (2000) 464-469
7. Gale R.P., and Reisner Y. Graft rejection and graft-versus-host disease: mirror images. Lancet 1 8496 (1986) 1468-1470
8. Kernan N.A., Flomenberg N., Dupont B., and O'Reilly R.J. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes. Transplantation 43 6 (1987) 842-847
9. Reisner Y., Kapoor N., Kirkpatrick D., Pollack M.S., Cunningham-Rundles S., Dupont B., et al. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 61 2 (1983) 341-348
10. Friedrich W., Goldmann S.F., Vetter U., Fliedner T.M., Heymer B., Peter H.H., et al. Immunoreconstitution in severe combined immunodeficiency after transplantation of HLA-haploidentical, T-cell-depleted bone marrow. Lancet 1 8380 (1984) 761-764
11. Fischer A., Durandy A., de Villartay J.P., Vilmer E., Le Deist F., Gerota I., et al. HLA-haploidentical bone marrow transplantation for severe combined immunodeficiency using E rosette fractionation and cyclosporine. Blood 67 2 (1986) 444-449
12. Buckley R.H., Schiff S.E., Sampson H.A., Schiff R.I., Markert M.L., Knutsen A.P., et al. Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation. J Immunol 136 7 (1986) 2398-2407
13. O'Reilly R.J. Hematopoietic cell transplantation. 2nd ed. (2004), Blackwell Science, Malden
14. Buckley R.H., Schiff S.E., Schiff R.I., Markert L., Williams L.W., Roberts J.L., et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 340 7 (1999) 508-516
15. Reisner Y., Ben-Bassat I., Douer D., Kaploon A., Schwartz E., and Ramot B. Demonstration of clonable alloreactive host T cells in a primate model for bone marrow transplantation. Proc Natl Acad Sci U S A 83 11 (1986) 4012-4015
16. Terenzi A., Aversa F., Albi N., Galandrini R., Dembech C., Velardi A., et al. Residual clonable host cell detection for predicting engraftment of T cell depleted BMTs. Bone Marrow Transplant 11 5 (1993) 357-361
17. Murphy W.J., Kumar V., Cope J.C., and Bennett M. An absence of T cells in murine bone marrow allografts leads to an increased susceptibility to rejection by natural killer cells and T cells. J Immunol 144 9 (1990) 3305-3311
18. Martin P.J. Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: potential role of a veto mechanism. Blood 88 3 (1996) 962-969
19. Lapidot T., Lubin I., Terenzi A., Faktorowich Y., Erlich P., and Reisner Y. Enhancement of bone marrow allografts from nude mice into mismatched recipients by T cells void of graft-versus-host activity. Proc Natl Acad Sci U S A 87 12 (1990) 4595-4599
20. Aversa F., Terenzi A., Tabilio A., Falzetti F., Carotti A., Ballanti S., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23 15 (2005) 3447-3454
21. Martelli M.F., Aversa F., Bachar-Lustig E., Velardi A., Reich-Zelicher S., Tabilio A., et al. Transplants across human leukocyte antigen barriers. Semin Hematol 39 1 (2002) 48-56
22. Ildstad S.T., Wren S.M., Bluestone J.A., Barbieri S.A., and Sachs D.H. Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity, and genetic specificity of tolerance. J Exp Med 162 1 (1985) 231-244
23. Ruedi E., Sykes M., Ildstad S.T., Chester C.H., Althage A., Hengartner H., et al. Antiviral T cell competence and restriction specificity of mixed allogeneic (P1 + P2-P1) irradiation chimeras. Cell Immunol 121 1 (1989) 185-195
24. Lapidot T., Terenzi A., Singer T.S., Salomon O., and Reisner Y. Enhancement by dimethyl myleran of donor type chimerism in murine recipients of bone marrow allografts. Blood 73 7 (1989) 2025-2032
25. Bachar-Lustig E., Rachamim N., Li H.W., Lan F., and Reisner Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1 12 (1995) 1268-1273
26. Uharek L., Gassmann W., Glass B., Steinmann J., Loeffler H., and Mueller-Ruchholtz W. Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. Blood 79 6 (1992) 1612-1621
27. Sheridan W.P., Begley C.G., Juttner C.A., Szer J., To L.B., Maher D., et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339 8794 (1992) 640-644
28. Bensinger W., Singer J., Appelbaum F., Lilleby K., Longin K., Rowley S., et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 81 11 (1993) 3158-3163
29. Aversa F., Tabilio A., Terenzi A., Velardi A., Falzetti F., Giannoni C., et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84 11 (1994) 3948-3955
30. Reisner Y., and Martelli M.F. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol Today 16 9 (1995) 437-440
31. Redei I., Langston A., Cherry J., Allen A., and Bartlett V. E. W. Haploidentical transplantation for adults with poor prognostic hematologic malignancies using the Perugia approach. Leukemia 16 (2002) 414
32. Zuckerman T., Haddad N., Elhasis R., and Rowe J.M. Haploidentical transplantation - a single center experience. Leukemia 16 (2002) 417
33. Handgretinger R., Klingebiel T., Lang P., Schumm M., Bader P., Schlegel P., et al. Haploidentical transplantation in children with hematological malignancies and non-malignant disorders. A single center 5-year experience. Leukemia 16 (2002) 410
34. Cornish J., Goulden N., Sewaard C., and Oakhill A. Haploidenticl stem cell transplantation in children. Leukemia 6 (2002) 408
35. Klingebiel T., Lang P., Schumm M., Bader P., Schlegel P., Eyrich M., et al. Haploidentical stem cell transplantation in children. Leukemia 16 (2002) 410
36. Rachamim N., Gan J., Segall H., Krauthgamer R., Marcus H., Berrebi A., et al. Tolerance induction by "megadose" hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation 65 10 (1998) 1386-1393
37. Gur H., Krauthgamer R., Bachar-Lustig E., Katchman H., Arbel-Goren R., Berrebi A., et al. Immune regulatory activity of CD34+ progenitor cells: evidence for a deletion-based mechanism mediated by TNF-alpha. Blood 105 6 (2005) 2585-2593
38. Miller R.G. An immunological suppressor cell inactivating cytotoxic T-lymphocyte precursor cells recognizing it. Nature 287 5782 (1980) 544-546
39. Bachar-Lustig E., Li H.W., Gur H., Krauthgamer R., Marcus H., and Reisner Y. Induction of donor-type chimerism and transplantation tolerance across major histocompatibility barriers in sublethally irradiated mice by Sca-1(+)Lin(-) bone marrow progenitor cells: synergism with non-alloreactive (host × donor)F(1) T cells. Blood 94 9 (1999) 3212-3221
40. Claesson M.H., and Miller R.G. Functional heterogeneity in allospecific cytotoxic T lymphocyte clones. III. Direct correlation between development of syngeneic cytotoxicity and loss of veto activity; implications for the mechanism of veto action. Scand J Immunol 29 4 (1989) 493-497
41. Claesson M.H., and Ropke C. Antiself suppressive (veto) activity of responder cells in mixed lymphocyte cultures. Curr Top Microbiol Immunol 126 (1986) 213-223
42. Fink P.J., Rammensee H.G., Benedetto J.D., Staerz U.D., Lefrancois L., and Bevan M.J. Studies on the mechanism of suppression of primary cytotoxic responses by cloned cytotoxic T lymphocytes. J Immunol 133 4 (1984) 1769-1774
43. Reich-Zeliger S., Bachar-Lustig E., Gan J., and Reisner Y. Tolerance induction by veto CTLs in the TCR transgenic 2C mouse model. I. Relative reactivity of different veto cells. J Immunol 173 11 (2004) 6654-6659
44. Reich-Zeliger S., Gan J., Bachar-Lustig E., and Reisner Y. Tolerance induction by veto CTLs in the TCR transgenic 2C mouse model. II. Deletion of effector cells by Fas-Fas ligand apoptosis. J Immunol 173 11 (2004) 6660-6666
45. Reich-Zeliger S., Zhao Y., Krauthgamer R., Bachar-Lustig E., and Reisner Y. Anti-third party CD8+ CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite. Immunity 13 4 (2000) 507-515
46. Lapidot T., Faktorowich Y., Lubin I., and Reisner Y. Enhancement of T-cell-depleted bone marrow allografts in the absence of graft-versus-host disease is mediated by CD8+CD4- and not by CD8-CD4+ thymocytes. Blood 80 9 (1992) 2406-2411
47. Bachar-Lustig E., Reich-Zeliger S., and Reisner Y. Anti-third-party veto CTLs overcome rejection of hematopoietic allografts: synergism with rapamycin and BM cell dose. Blood 102 6 (2003) 1943-1950
48. Adams A.B., Williams M.A., Jones T.R., Shirasugi N., Durham M.M., Kaech S.M., et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 111 12 (2003) 1887-1895
49. Pantenburg B., Heinzel F., Das L., Heeger P.S., and Valujskikh A. T cells primed by Leishmania major infection cross-react with alloantigens and alter the course of allograft rejection. J Immunol 169 7 (2002) 3686-3693
50. Wu Z., Bensinger S.J., Zhang J., Chen C., Yuan X., Huang X., et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 10 1 (2004) 87-92
51. Chen Y., Heeger P.S., and Valujskikh A. In vivo helper functions of alloreactive memory CD4+ T cells remain intact despite donor-specific transfusion and anti-CD40 ligand therapy. J Immunol 172 9 (2004) 5456-5466
52. Sanchez-Fueyo A., Sandner S., Habicht A., Mariat C., Kenny J., Degauque N., et al. Specificity of CD4+CD25+ regulatory T cell function in alloimmunity. J Immunol 176 1 (2006) 329-334
53. Lee M.K.t., Moore D.J., Jarrett B.P., Lian M.M., Deng S., Huang X., et al. Promotion of allograft survival by CD4+CD25+ regulatory T cells: evidence for in vivo inhibition of effector cell proliferation. J Immunol 172 11 (2004) 6539-6544
54. Yang J., Brook M.O., Carvalho-Gaspar M., Zhang J., Ramon H.E., Sayegh M.H., et al. Allograft rejection mediated by memory T cells is resistant to regulation. Proc Natl Acad Sci U S A 104 50 (2007) 19954-19959
55. Reich-Zeliger S., Bachar-Lustig E., Bar-Ilan A., and Reisner Y. Tolerance induction in presensitized bone marrow recipients by veto CTLs: effective deletion of host anti-donor memory effector cells. J Immunol 179 10 (2007) 6389-6394
56. Aviner S., Yao X., Krauthgamer R., Gan Y., Goren-Arbel R., Klein T., et al. Large-scale preparation of human anti-third-party veto cytotoxic T lymphocytes depleted of graft-versus-host reactivity: a new source for graft facilitating cells in bone marrow transplantation. Hum Immunol 66 (2005) 644-652
57. Arditti F.D., Aviner S., Dekel B., Krauthgamer R., Gan J., Nagler A., et al. Eradication of B-CLL by autologous and allogeneic host nonreactive anti-third-party CTLs. Blood 105 8 (2005) 3365-3371
58. Lask A., Goihberg P., Goren-Arbel R., Milstein O., Aviner S., Feine I., Klein T., Berrebi A., and Reisner Y. Eradication of B cell malignancies by anti-3rd party CTLs: a novel role for MHC class I. Blood 10 11 (2007) a2759
59. Gur H., Krauthgamer R., Berrebi A., Klein T., Nagler A., Tabilio A., et al. Tolerance induction by megadose hematopoietic progenitor cells: expansion of veto cells by short-term culture of purified human CD34(+) cells. Blood 99 11 (2002) 4174-4181
60. Reisner Y., Reich-Zeliger S., and Bachar-Lustig E. The role of veto cells in bone marrow transplantation. Curr Opin Organ Transplant 11 (2006) 366-372